In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Atara Biotherapeutics, Inc.. Trade Record

NASDAQ:ATRA Atara Biotherapeutics, Inc. stock gains 5.98% Exit Feb 21, 2019 a Trade Record by priceseries

Trade Chart
Trade Chart ATRA Jan 30, 2019, priceSeries
About Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of muscle wasting conditions and oncology. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. The company is also developing STM 434, a targeted therapy for ovarian cancer and other solid tumors; and a pipeline of product candidates that are in preclinical development. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in Brisbane, California.

Trade Information
Trade Type
LONG
ReliabilityScore™
95.95
Entry Date
Jan 30, 2019
Entry Price
36.17
Sell Date
Feb 21, 2019
Sell Price
38.33
Net Gain
5.98%
Hold Time
15 Trading Days